Aurobindo Pharma ko USFDA se Perampanel tablets banane ka final approval mil gaya hai. Ye drug epilepsy ke treatment mein kaam aati hai aur company ise Q3FY27 mein launch karegi.
Aurobindo ki nayi regulatory jeet
Aurobindo Pharma ne US market ke liye ek bada hurdle cross kar liya hai. Company ko epilepsy treatment mein use hone wali Perampanel tablets ke liye USFDA se final approval mil chuka hai. Ye tablets 2 mg se 12 mg ki strength mein available hongi.
Kitna bada hai opportunity?
Ye drug Catalyst Pharmaceuticals ki 'Fycompa' ka generic version hai. Data ke mutabik, US mein is drug ka market size lagbhag US$ 67 million ka hai, jo ki Aurobindo ke liye ek solid revenue opportunity ho sakti hai. Iske saath hi company ki total USFDA approvals ki sankhya ab 599 tak pahunch gayi hai, jisme 574 final aur 25 tentative approvals shamil hain.
Launch kab hoga?
Company ne is product ko Q3FY27 mein market mein utaarne ka plan banaya hai. Manufacturing unki Unit-IV facility (APL Healthcare) mein hogi. Investors ke liye ye track karna zaroori hai ki launch ke waqt competition ka kya scene rehta hai, kyunki generic drugs aane se aksar US market mein pricing pressure ban jata hai.
Overall, Aurobindo apna US portfolio lagatar strong kar rahi hai, jo unke long-term growth ke liye positive signal hai.